Sana Biotechnology, Inc. (SANA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.85-1.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SANA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SANA — earnings in line
Dated 2026-05-11
Results of Operations and Financial Condition. On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or othe…
Why it matters: A new investment would show strong trust in SC451's growth and partnership.
Supportive ifMayo Clinic invests an extra $25 million in Sana.
Worry ifMayo Clinic chooses not to make the extra investment.
Why it matters: The presentation will show how well UP421 works. Good results could help Sana's therapies.
Watch forLook for good feedback or data from the UP421 presentation on October 2.
Also watch forWatch for negative feedback or weak data from the UP421 presentation.
Why it matters: Watching cash burn is important for checking financial health. A big rise could mean bigger problems.
Worry ifNon-GAAP operating cash burn for Q2 2026 is lower than $37 million.
Less concerning ifNon-GAAP operating cash burn is over $37 million, showing cash flow is getting worse.
Why it matters: Earnings results will show cash flow and how the company is doing.
Watch forEarnings show less cash burn and better financial numbers than Q1.
Also watch forEarnings show more cash burn or worse financial numbers.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $841 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,473 loss on $10,000 · 54.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Advancing these trials is key for Sana's future product pipeline and growth.
Supportive ifThere is news about good trial results or important milestones in SC451 or SG293.
Worry ifDelays or setbacks reported in the SC451 or SG293 clinical trials.
Why it matters: First data from SG293 may show it can treat non-Hodgkin lymphoma and autoimmune diseases.
Supportive ifSana shares positive first data for SG293 in non-Hodgkin lymphoma this year.
Worry ifSG293 data shows safety issues or fails to meet efficacy benchmarks.
Why it matters: Good data could increase trust in SG293's effectiveness and market potential. This is important for investor feelings.
Supportive ifSana shows good early data for SG293 at the ASGCT Annual Meeting on May 12.
Worry ifThe data shown is unclear or negative, raising doubts about SG293's success.
Why it matters: Starting the SC451 trial is key for advancing treatment for type 1 diabetes. It shows progress in clinical development.
Supportive ifSana files the IND and begins the Phase 1/2 trial for SC451 as planned this year.
Worry ifSana delays the IND filing or trial start beyond 2026.
Why it matters: Starting the SG293 study is important for new treatments for non-Hodgkin lymphoma. It shows progress in clinical trials.
Supportive ifSana begins the clinical study for SG293 as planned this year.
Worry ifSana delays the SG293 study start beyond 2026.
Why it matters: Progress with the Mayo Clinic could help SC451's development and market chances.
Supportive ifSana shares key milestones reached with the Mayo Clinic.
Worry ifNo updates or setbacks in the partnership's progress are reported.
Why it matters: Good results from UP421 could increase trust in Sana's method for treating type 1 diabetes.
Watch forThe presentation shows strong data. This data supports UP421's safety and effectiveness.
Also watch forThe presentation shows worries or weak data about how UP421 is performing.